{"id":9004111222133275,"date":"2025-09-04T09:20:52","date_gmt":"2025-09-04T08:20:52","guid":{"rendered":"https:\/\/www.hgf.com\/?p=9004111222133275"},"modified":"2026-02-23T10:24:55","modified_gmt":"2026-02-23T10:24:55","slug":"novelty-over-clinical-trials-at-the-epo","status":"publish","type":"post","link":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/","title":{"rendered":"Novelty Over Clinical Trials at the EPO"},"content":{"rendered":"<p>Video overview:<\/p>\n<p>Second medical use claims can be novel over clinical trials in European patents.<\/p>\n<p>Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and dosages for a potential commercial product.<\/p>\n<p>For such a claim to be novel, it is important that the prior art disclosure of the clinical trial does not unambiguously disclose the therapeutic effect underlying the claim.\u00a0 The EPO\u2019s approach to this is explained in more detail in the video.<\/p>\n<div class=\"wistia_responsive_padding\" style=\"padding: 56.25% 0 0 0; position: relative;\">\n<div class=\"wistia_responsive_wrapper\" style=\"height: 100%; left: 0; position: absolute; top: 0; width: 100%;\"><iframe class=\"wistia_embed\" title=\"Novelty Over Clinical Trials Video\" src=\"https:\/\/fast.wistia.net\/embed\/iframe\/b0wsoqkh53?seo=true&amp;videoFoam=true\" name=\"wistia_embed\" width=\"100%\" height=\"100%\" frameborder=\"0\" scrolling=\"no\"><\/iframe><\/div>\n<\/div>\n<p><script src=\"https:\/\/fast.wistia.net\/assets\/external\/E-v1.js\" async><\/script><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Video overview: Second medical use claims can be novel over clinical trials in European patents. Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and &hellip;<\/p>\n","protected":false},"author":376,"featured_media":9004111222133415,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[507,497],"tags":[],"class_list":["post-9004111222133275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hgf-presents","category-knowledge-hub","service-patents"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novelty Over Clinical Trials at the EPO - HGF<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novelty Over Clinical Trials at the EPO\" \/>\n<meta property=\"og:description\" content=\"Video overview: Second medical use claims can be novel over clinical trials in European patents. Typically, such a claim would be fairly narrow, e.g.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/\" \/>\n<meta property=\"og:site_name\" content=\"HGF\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-04T08:20:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T10:24:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/09\/Untitled-design-35-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Emily Long\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hgf_ip\" \/>\n<meta name=\"twitter:site\" content=\"@hgf_ip\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emily Long\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/\"},\"author\":{\"name\":\"Emily Long\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/person\\\/6448009bfef4595c7093543a41ec843d\"},\"headline\":\"Novelty Over Clinical Trials at the EPO\",\"datePublished\":\"2025-09-04T08:20:52+00:00\",\"dateModified\":\"2026-02-23T10:24:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/\"},\"wordCount\":88,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Untitled-design-35-1.png\",\"articleSection\":[\"HGF Presents\",\"Knowledge Hub\"],\"inLanguage\":\"de-DE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/\",\"name\":\"Novelty Over Clinical Trials at the EPO - HGF\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Untitled-design-35-1.png\",\"datePublished\":\"2025-09-04T08:20:52+00:00\",\"dateModified\":\"2026-02-23T10:24:55+00:00\",\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/hgf-presents\\\/novelty-over-clinical-trials-at-the-epo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Untitled-design-35-1.png\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Untitled-design-35-1.png\",\"width\":1920,\"height\":1080},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/\",\"name\":\"HGF\",\"description\":\"Intellectual Property Rights specialists\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\",\"name\":\"HGF\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"width\":696,\"height\":696,\"caption\":\"HGF\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hgf_ip\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hgf-limited-intellectual-property-specialists\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/person\\\/6448009bfef4595c7093543a41ec843d\",\"name\":\"Emily Long\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ee8a842b2c13d2e469b54f812f8d3a508eecb74efb5654ce323a409c33faf169?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ee8a842b2c13d2e469b54f812f8d3a508eecb74efb5654ce323a409c33faf169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ee8a842b2c13d2e469b54f812f8d3a508eecb74efb5654ce323a409c33faf169?s=96&d=mm&r=g\",\"caption\":\"Emily Long\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novelty Over Clinical Trials at the EPO - HGF","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/","og_locale":"de_DE","og_type":"article","og_title":"Novelty Over Clinical Trials at the EPO","og_description":"Video overview: Second medical use claims can be novel over clinical trials in European patents. Typically, such a claim would be fairly narrow, e.g.","og_url":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/","og_site_name":"HGF","article_published_time":"2025-09-04T08:20:52+00:00","article_modified_time":"2026-02-23T10:24:55+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/09\/Untitled-design-35-1.png","type":"image\/png"}],"author":"Emily Long","twitter_card":"summary_large_image","twitter_creator":"@hgf_ip","twitter_site":"@hgf_ip","twitter_misc":{"Verfasst von":"Emily Long"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/#article","isPartOf":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/"},"author":{"name":"Emily Long","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/person\/6448009bfef4595c7093543a41ec843d"},"headline":"Novelty Over Clinical Trials at the EPO","datePublished":"2025-09-04T08:20:52+00:00","dateModified":"2026-02-23T10:24:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/"},"wordCount":88,"publisher":{"@id":"https:\/\/www.hgf.com\/de\/#organization"},"image":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/09\/Untitled-design-35-1.png","articleSection":["HGF Presents","Knowledge Hub"],"inLanguage":"de-DE"},{"@type":"WebPage","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/","url":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/","name":"Novelty Over Clinical Trials at the EPO - HGF","isPartOf":{"@id":"https:\/\/www.hgf.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/#primaryimage"},"image":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/09\/Untitled-design-35-1.png","datePublished":"2025-09-04T08:20:52+00:00","dateModified":"2026-02-23T10:24:55+00:00","inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/hgf-presents\/novelty-over-clinical-trials-at-the-epo\/#primaryimage","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/09\/Untitled-design-35-1.png","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/09\/Untitled-design-35-1.png","width":1920,"height":1080},{"@type":"WebSite","@id":"https:\/\/www.hgf.com\/de\/#website","url":"https:\/\/www.hgf.com\/de\/","name":"HGF","description":"Intellectual Property Rights specialists","publisher":{"@id":"https:\/\/www.hgf.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hgf.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.hgf.com\/de\/#organization","name":"HGF","url":"https:\/\/www.hgf.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","width":696,"height":696,"caption":"HGF"},"image":{"@id":"https:\/\/www.hgf.com\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hgf_ip","https:\/\/www.linkedin.com\/company\/hgf-limited-intellectual-property-specialists\/"]},{"@type":"Person","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/person\/6448009bfef4595c7093543a41ec843d","name":"Emily Long","image":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/secure.gravatar.com\/avatar\/ee8a842b2c13d2e469b54f812f8d3a508eecb74efb5654ce323a409c33faf169?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ee8a842b2c13d2e469b54f812f8d3a508eecb74efb5654ce323a409c33faf169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ee8a842b2c13d2e469b54f812f8d3a508eecb74efb5654ce323a409c33faf169?s=96&d=mm&r=g","caption":"Emily Long"}}]}},"_links":{"self":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts\/9004111222133275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/users\/376"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/comments?post=9004111222133275"}],"version-history":[{"count":0,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts\/9004111222133275\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/media\/9004111222133415"}],"wp:attachment":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/media?parent=9004111222133275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/categories?post=9004111222133275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/tags?post=9004111222133275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}